Market Overview

US Patent Office Issues Decision to Grant Patent for USMI's Cold Atmospheric Plasma for the Selective Ablation of Cancer Cells

Share:

US
Medical Innovations, LLC (USMI)
, a U.S. FDA registered life
science, biomedical and robotic device company (a subsidiary of US
Patent Innovations, LLC), announced today that the United States Patent
Office (USPO) has issued USPI patent No. 10,023,858 B2, further
expanding its intellectual patent property portfolio for the application
of delivering Cold Atmospheric Plasma (CAP) technology to selectively
target cancer cells.

Researchers at the Jerome Canady Research Institute for Advanced
Biological and Technological Sciences (JCRI-ABTS), Takoma Park, Md.,
have successfully demonstrated the use of CAP for elevating TRAIL-R1
(Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)
receptor 1 expression in cancer cells to induce apoptosis.

Dr. Canady (CEO of JCRI-ABTS and USMI) commented, "Breast cancer
represents 23% of total cancer cases and 14% of the deaths related to
cancers. These cancers are identified by subtypes and the presence or
absence of the estrogen receptor (ER), progesterone receptor (PR), and
human epidermal growth factor receptor type 2 (HER 2). Patients with
HER2 positive breast tumors have the second poorest survival among
breast cancer subtypes."

Utilizing USMI's patented electrosurgical plasma system, CAP is
delivered through the Canady Helios™ Plasma Scalpel, in conjunction with
this patented process for elevating a TRAIL-R1 expression in cancer
cells, to induce apoptosis. The method entails the steps involved in
using electrical energy with a specific voltage, frequency and power
from the Cold Plasma Generator (recently issued patent no. 9,999,452)
and applying the cold plasma to the surgical margins to target cancer
cells. The invention identifies the involvement of a new receptor in
plasma medicine, a Tumor Necrosis Factor (TNF) inducing ligand (TRAIL).
The TRAIL receptor 1 (TRAIL R-1) activates apoptosis through the death
receptors DR4 and DR5. In breast cancer epithelial cells, TRAIL R-1
expression was elevated when treated with CAP while normal breast cells
were unaffected.

Dr. Canady additionally commented, "Two decades ago, a humanized
monoclonal antibody (mAb) against HER2 was developed and has improved
HER2 positive breast cancer patient's overall survival. Trastuzumab
(sold under the brand name Herceptin, a registered trademark of
Genentech), is a humanized monoclonal antibody approved by the FDA. Our
new patented technology will be an adjunct therapy for treating solid
cancerous tumors, especially HER2, Estrogen, Progesterone, and Triple
negative receptor breast cancers, as well as promising for those
patients who may develop a resistance to Trastuzumab. We plan to begin a
multi-center international clinical trial this summer."

About US Medical Innovations

US Medical Innovations, LLC (USMI), based out of Takoma Park, MD, is a
privately-held FDA-registered life science, biomedical and robotic
device company. USMI is dedicated to expanding the boundaries of plasma
medicine by pioneering new technologies for the development of
state-of-the-art medical devices that advance patient outcomes and
improve human lives.

View Comments and Join the Discussion!